News

Higher levels of a protein called amyloid precursor protein (APP) in the blood may be a marker of fibrosis, or liver scarring, in biliary…

The safety monitoring committee of a Phase 2a clinical trial testing zetomipzomib in people with autoimmune hepatitis has found no major safety issues with…

The U.S. Food and Drug Administration (FDA) is still reviewing Intercept Pharmaceuticals’ application for full approval of Ocaliva (obeticholic acid) as a second-line…

Excessive copper levels in the body led to an initial misdiagnosis of Wilson disease, a rare condition marked by copper buildup in the liver and…

Suppressing the production of the SPTBN1 protein reduces liver fat, inflammation, and scarring (fibrosis) in mouse and human models of two forms of fatty…

Alterations to the immune system may underlie the mild liver scarring, or fibrosis, that characterizes Alagille syndrome despite severe liver disease, according to a…

Fewer than half of reproductive-aged women with opioid use disorder in the U.S. undergo hepatitis C testing, with Black and Asian women less likely…

The U.S. Food and Drug Administration (FDA) has designated Mirum Pharmaceuticals’ oral candidate volixibat a breakthrough therapy for the treatment of itching, or…

A new ABCB11 gene mutation was the likely cause of progressive familial intrahepatic cholestasis type 2 (PFIC2) in a boy who was also born with…

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to survodutide, an experimental injectable therapy by Boehringer Ingelheim for metabolic dysfunction-associated steatohepatitis…